

IN THE CLAIMS

The following listing of claims will replace all prior versions and listings of claims in the present application.

1–3 (cancelled).

4–10 (withdrawn).

11 (cancelled).

12–20 (withdrawn).

21 (cancelled).

22–42 (withdrawn).

43–46 (cancelled).

47–53 (withdrawn).

54 (cancelled).

55–70 (withdrawn).

71 (cancelled).

72–85 (withdrawn).

86–87 (cancelled).

88–106 (withdrawn).

107–108 (cancelled).

109 (withdrawn).

110 (currently amended). ~~The method of claim 1~~ A method for treating a neoplasia disorder in a mammal in need of such treatment, which method comprises administering to said mammal a therapeutically-effective amount of the matrix metalloproteinase inhibitor N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-3-thiomorpholinecarboxamide and an

June 17, 2004

antineoplastic agent selected from the group consisting of irinotecan and topotecan and a combination thereof, wherein the neoplasia disorder is lung cancer.

111 (currently amended). ~~The method of claim 1~~ A method for treating a neoplasia disorder in a mammal in need of such treatment, which method comprises administering to said mammal a therapeutically-effective amount of the matrix metalloproteinase inhibitor N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-3-thiomorpholinecarboxamide and an antineoplastic agent selected from the group consisting of irinotecan and topotecan and a combination thereof, wherein the neoplasia disorder is colorectal cancer.

112 (currently amended). ~~The method of claim 1~~ A method for treating a neoplasia disorder in a mammal in need of such treatment, which method comprises administering to said mammal a therapeutically-effective amount of the matrix metalloproteinase inhibitor N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-3-thiomorpholinecarboxamide and an antineoplastic agent selected from the group consisting of irinotecan and topotecan and a combination thereof, wherein the neoplasia disorder is breast cancer.

113 (currently amended). ~~The method of claim 1~~ A method for treating a neoplasia disorder in a mammal in need of such treatment, which method comprises administering to said mammal a therapeutically-effective amount of the matrix metalloproteinase inhibitor N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-3-thiomorpholinecarboxamide and an antineoplastic agent selected from the group consisting of irinotecan and topotecan and a combination thereof, wherein the neoplasia disorder is prostate cancer.

114 (currently amended). ~~The method of claim 1~~ A method for treating a

June 17, 2004

neoplasia disorder in a mammal in need of such treatment, which method comprises administering to said mammal a therapeutically-effective amount of the matrix metalloproteinase inhibitor N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-3-thiomorpholinecarboxamide and an antineoplastic agent selected from the group consisting of irinotecan and topotecan and a combination thereof, wherein the neoplasia disorder is bladder cancer.

115 (currently amended). ~~The method of claim 1~~ A method for treating a neoplasia disorder in a mammal in need of such treatment, which method comprises administering to said mammal a therapeutically-effective amount of the matrix metalloproteinase inhibitor N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-3-thiomorpholinecarboxamide and an antineoplastic agent selected from the group consisting of irinotecan and topotecan and a combination thereof, wherein the neoplasia disorder is ovary cancer.

116 (currently amended). ~~The method of claim 1~~ A method for treating a neoplasia disorder in a mammal in need of such treatment, which method comprises administering to said mammal a therapeutically-effective amount of the matrix metalloproteinase inhibitor N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-3-thiomorpholinecarboxamide and an antineoplastic agent selected from the group consisting of irinotecan and topotecan and a combination thereof, wherein the neoplasia disorder is cervical cancer.

117 (currently amended). ~~The method of claim 1~~ A method for treating a neoplasia disorder in a mammal in need of such treatment, which method comprises administering to said mammal a therapeutically-effective amount of the matrix metalloproteinase inhibitor N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-3-thiomorpholinecarboxamide and an antineoplastic agent selected from the group consisting of irinotecan and

June 17, 2004

topotecan and a combination thereof, wherein the neoplasia disorder is gastrointestinal cancer.

118 (currently amended). ~~The method of claim 1-~~ A method for treating a neoplasia disorder in a mammal in need of such treatment, which method comprises administering to said mammal a therapeutically-effective amount of the matrix metalloproteinase inhibitor N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-3-thiomorpholinecarboxamide and an antineoplastic agent selected from the group consisting of irinotecan and topotecan and a combination thereof, wherein the neoplasia disorder is head and neck cancer.

119 (currently amended). ~~The method of claim 44-~~ A method for treating a neoplasia disorder in a mammal in need of such treatment, which method comprises administering to said mammal a therapeutically-effective amount of radiation therapy, the matrix metalloproteinase inhibitor N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-3-thiomorpholinecarboxamide and an antineoplastic agent selected from the group consisting of irinotecan and topotecan and a combination thereof, wherein the neoplasia disorder is lung cancer.

120 (currently amended). ~~The method of claim 44-~~ A method for treating a neoplasia disorder in a mammal in need of such treatment, which method comprises administering to said mammal a therapeutically-effective amount of radiation therapy, the matrix metalloproteinase inhibitor N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-3-thiomorpholinecarboxamide and an antineoplastic agent selected from the group consisting of irinotecan and topotecan and a combination thereof, wherein the neoplasia disorder is colorectal cancer.

121 (currently amended). ~~The method of claim 44-~~ A method for treating a neoplasia disorder in a mammal in need of such treatment, which method

June 17, 2004

comprises administering to said mammal a therapeutically-effective amount of radiation therapy, the matrix metalloproteinase inhibitor N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-3-thiomorpholinecarboxamide and an antineoplastic agent selected from the group consisting of irinotecan and topotecan and a combination thereof, wherein the neoplasia disorder is breast cancer.

122 (currently amended). ~~The method of claim 44~~ A method for treating a neoplasia disorder in a mammal in need of such treatment, which method comprises administering to said mammal a therapeutically-effective amount of radiation therapy, the matrix metalloproteinase inhibitor N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-3-thiomorpholinecarboxamide and an antineoplastic agent selected from the group consisting of irinotecan and topotecan and a combination thereof, wherein the neoplasia disorder is prostate cancer.

123 (currently amended). ~~The method of claim 44~~ A method for treating a neoplasia disorder in a mammal in need of such treatment, which method comprises administering to said mammal a therapeutically-effective amount of radiation therapy, the matrix metalloproteinase inhibitor N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-3-thiomorpholinecarboxamide and an antineoplastic agent selected from the group consisting of irinotecan and topotecan and a combination thereof, wherein the neoplasia disorder is bladder cancer.

124 (currently amended). ~~The method of claim 44~~ A method for treating a neoplasia disorder in a mammal in need of such treatment, which method comprises administering to said mammal a therapeutically-effective amount of radiation therapy, the matrix metalloproteinase inhibitor N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-3-thiomorpholinecarboxamide and an antineoplastic agent selected from the group consisting of irinotecan and topotecan and a combination thereof, wherein the neoplasia disorder is ovary

June 17, 2004

cancer.

125 (currently amended). ~~The method of claim 44~~ A method for treating a neoplasia disorder in a mammal in need of such treatment, which method comprises administering to said mammal a therapeutically-effective amount of radiation therapy, the matrix metalloproteinase inhibitor N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-3-thiomorpholinecarboxamide and an antineoplastic agent selected from the group consisting of irinotecan and topotecan and a combination thereof, wherein the neoplasia disorder is cervical cancer.

126 (currently amended). ~~The method of claim 44~~ A method for treating a neoplasia disorder in a mammal in need of such treatment, which method comprises administering to said mammal a therapeutically-effective amount of radiation therapy, the matrix metalloproteinase inhibitor N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-3-thiomorpholinecarboxamide and an antineoplastic agent selected from the group consisting of irinotecan and topotecan and a combination thereof, wherein the neoplasia disorder is gastrointestinal cancer.

127 (currently amended). ~~The method of claim 44~~ A method for treating a neoplasia disorder in a mammal in need of such treatment, which method comprises administering to said mammal a therapeutically-effective amount of radiation therapy, the matrix metalloproteinase inhibitor N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-3-thiomorpholinecarboxamide and an antineoplastic agent selected from the group consisting of irinotecan and topotecan and a combination thereof, wherein the neoplasia disorder is head and neck cancer.

128 (currently amended). ~~The method of claim 107 wherein~~ A method for treating a neoplasia disorder of the lung in a mammal in need of such treatment, which method comprises administering to said mammal a

June 17, 2004

therapeutically-effective amount of the matrix metalloproteinase inhibitor N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-3-thiomorpholinecarboxamide and the antineoplastic agent ~~is~~ irinotecan.

129 (currently amended). ~~The method of claim 108 wherein~~ A method for treating a neoplasia disorder of the lung in a mammal in need of such treatment, which method comprises administering to said mammal a therapeutically-effective amount of radiation therapy, the matrix metalloproteinase inhibitor N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-3-thiomorpholinecarboxamide and the antineoplastic agent ~~is~~ irinotecan.

130 (currently amended). ~~The method of claim 107 wherein~~ A method for treating a neoplasia disorder of the lung in a mammal in need of such treatment, which method comprises administering to said mammal a therapeutically-effective amount of the matrix metalloproteinase inhibitor N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-3-thiomorpholinecarboxamide and the antineoplastic agent ~~is~~ topotecan.

131 (currently amended). ~~The method of claim 108 wherein~~ A method for treating a neoplasia disorder of the lung in a mammal in need of such treatment, which method comprises administering to said mammal a therapeutically-effective amount of radiation therapy, the matrix metalloproteinase inhibitor N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-3-thiomorpholinecarboxamide and the antineoplastic agent ~~is~~ topotecan.

132 (currently amended). ~~The combination of claim 87 wherein~~ A combination comprising the matrix metalloproteinase inhibitor N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-3-thiomorpholinecarboxamide and the antineoplastic agent ~~is~~ irinotecan.

133 (currently amended). ~~The combination of claim 87 wherein~~ A

Serial No. 09/857,995

6794F-000037/US/01 (3167/5Z/US)

Amendment after final action under 37 CFR §1.116 (Amendment D)

June 17, 2004

combination comprising the matrix metalloproteinase inhibitor N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-3-thiomorpholinecarboxamide and the antineoplastic agent ~~is~~ topotecan.